Diana Miao

Diana Miao

Auto-generated profile, based on publicly available information

Diana Miao

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DLDavid Liu
David Liu
BSBastian Schilling
Bastian Schilling
DLDerek Liu
Derek Liu
ASAntje Sucker
Antje Sucker
ELElisabeth Livingstone
Elisabeth Livingstone
DSDirk Schadendorf
Dirk Schadendorf
Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors. We found that tumor mutational burden as a predictor of response was confounded by melanoma subtype, whereas multiple novel genomic and transcriptomic features predicted selective response, including features associated with MHC-I and MHC-II antigen presentation. Furthermore, previous anti-CTLA4 ICB exposure was associated with different predictors of response compared to tumors that were naive to ICB, suggesting selective immune effects of previous exposure to anti-CTLA4 ICB. Finally, we developed parsimonious models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 ICB in individual tumors, with validation in smaller independent cohorts limited by the availability of comprehensive data. Broadly, we present a framework to discover predictive features and build models of ICB therapeutic response.

27 August 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DMDiana Miao
Diana Miao
CMClaire A. Margolis
Claire A. Margolis
NVNatalie I. Vokes
Natalie I. Vokes
DLDavid Liu
David Liu
ATAmaro Taylor-Weiner
Amaro Taylor-Weiner
EAEliezer Van Allen
Eliezer Van Allen

23 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ICIsrael Cañadas
Israel Cañadas
RTRohit Thummalapalli
Rohit Thummalapalli
JKJong Wook Kim
Jong Wook Kim
SKShunsuke Kitajima
Shunsuke Kitajima
RJRussell W. Jenkins
Russell W. Jenkins
DBDavid A Barbie
David A Barbie

19 June 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DLDavid Liu
David Liu
BSBastian Schilling
Bastian Schilling
DLDerek Liu
Derek Liu
ASAntje Sucker
Antje Sucker
ELElisabeth Livingstone
Elisabeth Livingstone
DSDirk Schadendorf
Dirk Schadendorf
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

10 January 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Guillermo De VelascoGuillermo De Velasco
Guillermo De Velasco
DMDiana Miao
Diana Miao
SSSachet Shukla
Sachet Shukla
MVMartin Henner Voss
Martin Henner Voss
CWCatherine Wu
Catherine Wu
TCToni K. Choueiri
Toni K. Choueiri
545 Background: Nivolumab (nivo) is a programmed death-1 (PD-1) inhibitor that has recently been shown to increase overall survival in patients with mRCC. The association between benefit from nivo with neoantigen load, mutation load and signatures of immune infiltration has yet to be explored in mRCC. Methods: Publicly available whole exomes (WES) and whole transcriptomes (RNA-seq) from over 300 clear-cell RCC patients in the Cancer Genome Atlas (TCGA) were analyzed for mutational load, neoantigen load and expression of immune-related genes. HLA types were inferred from WES with Polysolver and neoantigens were predicted from somatic nonsynonymous mutations with NetMHCpan3.2. The same analysis pipeline was applied to paired pre-treatment germline and metastatic tumor specimens from 9 patients who received nivo for mRCC: 3 responders (CR or PR by RECIST; R) and 6 non-responders (SD or PD by RECIST; NR), all with available pre-nivo fresh biopsies of metastatic lesions. Matched RNA-seq was available on a subset of these patient samples (3 R, 3 NR). Results: Across the TCGA and nivo-treated patients cohorts, RCC had relatively few nonsynonymous mutations and neoantigens. Among the nivo-treated patients, neoantigen load was significantly higher in NR compared to R (p = 0.048), but nonsynonymous mutation load was not. An exceptional R who experienced CR (PFS > 30 months) had outlying higher expression of selected immune-related genes compared to the 8 other patient samples (p < 0.05 for PD-L1, PD-L2; p < 0.01 for CTLA4, PD-1, PRF1; p < 0.001 for GZMA, BTLA, CD8A), and was in the top 1-5% of expression of these genes among all TCGA data. Bootstrapping analysis comparing mean expression in R vs NR compared to an empirical distribution of TCGA RNA-seq data showed significantly higher expression of PD-1, PD-L1, GZMA, LAG3, IDO1, ICOS, and BTLA in R vs. NR (p < 0.05). No genes were enriched for nonsynonymous mutations in R or NR. Conclusions: This analysis suggests that both DNA- and RNA-level data may be relevant for explaining clinical benefit from nivo in mRCC. In contrast with results from other tumor types, responders to nivo did not have more mutated tumors, though immune-related gene expression may be related to response.

27 April 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAlicia C. Smart
Alicia C. Smart
CMClaire A. Margolis
Claire A. Margolis
HPHarold Pimentel
Harold Pimentel
MHMeng Xiao He
Meng Xiao He
DMDiana Miao
Diana Miao
EAEliezer Van Allen
Eliezer Van Allen
Personalized cancer vaccine strategies directed at tumor neoantigens derived from somatic mutations in the DNA are currently under prospective evaluation 1, 2 . Alterations in tumor RNA, rather than DNA, may also represent a previously-unexplored source of neoantigens. Here, we show that intron retention, a widespread feature of cancer transcriptomes 3, 4 , represents a novel source of tumor neoantigens. We developed an in silico approach to identify retained intron neoantigens from RNA sequencing data and applied this methodology to tumor samples from patients with melanoma treated with immune checkpoint blockade 5, 6 , discovering that the retained intron neoantigen burden in these samples augments the DNA-derived, somatic neoantigen burden. We validated the existence of retained intron derived neoantigens by implementing this technique on cancer cell lines with mass spectrometry-derived immunopeptidome data 7, 8 , revealing that retained intron neoantigens were complexed with MHC I experimentally. Unexpectedly, we observed a trend toward lack of clinical benefit from immune checkpoint blockade in high retained intron load-tumors, which harbored transcriptional signatures consistent with cell cycle dysregulation and DNA damage repair. Our results demonstrate the contribution of transcriptional dysregulation to the overall burden of tumor neoantigens, provide a foundation for augmenting personalized cancer vaccine development with a new class of tumor neoantigens, and demonstrate how global transcriptional dysregulation may impact selective response to immune checkpoint blockade. Statement of significance: We developed and experimentally validated a computational pipeline to identify a novel class of tumor neoantigens derived from RNA-based intron retention, which is prevalent throughout cancer transcriptomes. The discovery of transcriptionally-derived tumor neoantigens expands the tumor immunopeptidome and contributes potential substrates for personalized cancer vaccine development.